Sotera Health said today it inked a deal to sell the medical isotopes segment of its Nordion business to a subsidiary of BWX Technologies for an undisclosed amount.
Through the deal, Broadview Heights, Ohio-based Sotera Health will divest itself of all of Nordion’s medical isotope assets, including its radiochemical operation and contract manufacturing services in Kanata and its medical isotope operation in Vancouver.
“The world’s need for gamma technology has expanded dramatically as the demand for sterilization of medical and non-medical applications has accelerated in response to increasing global regulatory demands and growing healthcare needs. The sale will enable BWXT to enter the medical isotope field with highly skilled employees and specialized facilities that are recognized as the best in the business. As the world’s only fully integrated provider of mission-critical services to the healthcare industry, Sotera Health is excited about the additional value Nordion will bring to our gamma customers, and our other best-in-class businesses, Sterigenics and Nelson Labs,” Sotera CEO Michael Petras said in a prepared statement.
Sotera Health said that both companies will continue to operate from Nordion’s Kanata, Ontario-based facility, and that 150 employees will transition to the BWX Tech subsidiary at the close of the sale.
“Nordion will continue to focus on accelerating growth in gamma technologies, including industrial and medical cobalt-60 which fits perfectly with Sotera Health’s broader mission of Safeguarding Global Health,” Nordion prez Kevin Brooks said in a press release.
Sotera Health was previously known as Sterigenics International, and is the parent company of Nelson Labs, Nordion and Sterigenics. The company renamed itself last November.
